Patent: 8,809,378

Summary for Patent: 8,809,378

Title:	Metalloenzyme inhibitor compounds
Abstract:	The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Inventor(s):	Hoekstra; William J. (Durham, NC), Rafferty; Stephen W. (Durham, NC), Yates; Christopher M. (Raleigh, NC), Schotzinger; Robert J. (Raleigh, NC), Loso; Michael R. (Carmel, IN), Sullenberger; Michael T. (Westfield, IN), Gustafson; Gary D. (Zionsville, IN)
Assignee:	Viamet Pharmaceuticals, Inc. (Durham, NC)
Application Number:	13/527,387
Patent Claims:	see list of patent claims

United States Patent 8,809,378 landscape: what claims 1-21 cover and where enforcement risk sits

US 8,809,378 is an agrochemical “Formula I” patent that claims broad compound coverage through extensive structural Markush ranges (MBG, R1–R12, x) and then narrows by (i) functional use on plants (treatment, prevention, growth inhibition) and (ii) specific enumerations of fungal diseases and fungal genera species. The claims are designed to capture a wide design-space of tetrazole/oxazole/pyrimidine/thiazole/pyrazole-containing difluorinated propan-2-ol scaffolds with substituted pyridyl or related heteroaryl motifs.

From an enforcement perspective, the estate is likely strongest against (a) products that use Formula I cores directly (spray/contact formulations and seed treatments), (b) close analogs that fall inside the Markush constraints on key heterocycles and substituents, and (c) label claims that match the claimed plant-based disease and microorganism lists. Enforcement is weaker against products that (i) move outside the Formula I core (especially changes to MBG class, the difluoro/di-fused substitution pattern, or the constrained substituent families), (ii) target non-metalloenzyme mechanisms, or (iii) avoid label scope that matches the claim recitations of fungal diseases and genera/species.

No complete, accurate “claims critical analysis” and no actionable “full patent landscape” can be produced from the information provided alone because US 8,809,378’s file history, specification definitions of Formula I, dependencies’ exact claim numbering/structure as issued, and the broader family members and citations are not supplied.

What does US 8,809,378 claim: treatment, prevention, and growth inhibition on plants?

The patent claims methods of using “a compound of Formula I” by contacting plants or seeds, covering both plant disease outcomes and microbial inhibition outcomes. Claims 1 and 3 cover “treating or preventing” metalloenzyme-mediated disease (plant) and fungal disease (plant), respectively. Claims 2 and 4-5 expand into inhibition of metalloenzyme activity (microorganism on plant), fungal growth, and microorganisms in or on a plant.

Core claim construct across claims 1-5

Each independent method claim follows the same skeleton:

1. Select a “compound of Formula I”
2. Contact the plant or seeds
3. Achieve a functional outcome, framed as:
   • metalloenzyme-mediated disease treatment/prevention (claim 1),
   • metalloenzyme activity inhibition in a microorganism on a plant (claim 2),
   • fungal disease treatment/prevention (claim 3),
   • fungal growth inhibition (claim 4),
   • microorganism inhibition on/in a plant (claim 5)

The breadth comes from the Markush-style Formula I definition. The claims do not require a specific formulation type (wettable powder, EC, SC, seed coating) or a dosage range in the text provided, which typically increases infringement surface area for contact/spray and seed-treatment products that can be tied to “contacting.”

Claim 6-17: narrowing dependent targets inside the same core “contact” framework

Claims 6-8 narrow R1 and/or R2 to fluoro. Claims 9-12 narrow R4 to phenyl and then to 2,4-difluorophenyl. Claims 13-17 further constrain R5 and R3. These are classic “fallback” limitations to defend against design-around by small substituent edits.

Claim 18: product-by-example anchor list

Claim 18 recites a long list of specific compounds (numbered 1–103 in the extract) that are stated to be “the compound is one of:” followed by example structures. This is important for infringement analysis because it creates a defined set of embodiments that are assured to fall within the Markush definition (assuming the specification ties the examples to Formula I).

In litigation terms, an accused product matching any listed compound is a clean infringement route, including where the accused product is hard to map to Markush limits except by direct structure comparison.

How broad is Formula I under the Markush ranges in claims 1-5?

The excerpt supplies the following key variable families:

• MBG: optionally substituted tetrazolyl, oxazolyl, pyrimidinyl, thiazolyl, or pyrazolyl
• R1: halo or haloalkyl
• R2: H, halo, alkyl, or haloalkyl
• R3: wide ring/chain families including alkyl/alkenyl/cycloalkyl/heteroaryl and substituted carbonyl/benzylic and fluorinated and heteroatom-containing groups; also “cyclic amino”
• R4: aryl, heteroaryl, or cycloalkyl
• R5 and R6: independent options including H/halo/alkyl/alkoxy/cyano/haloalkyl/haloalkoxy/halothioalkyl/thioalkyl/SF3/SF6/SCN/SO2R11/cycloalkyl and carboxylate-related and acyl/ester groups
• R7 and R8: aryl/alkoxy/halo/hydroxyl/cyano/acyloxy variants, with R7 able to be more diverse than R8
• R9: H, halo, or haloalkyl
• R10: H, alkyl, silyl, phosphonate, phosphonate-methylene, or C(O)alkyl optionally substituted with amino
• R11: alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl
• R12: alkyl or aryl
• x: 0–2 (a sulfur-oxide degree variable in “CH2S(O)x(aryl)” territory)

Practical read-across: where design-arounds usually fail

Even without the specification, the Markush choices indicate several structural “hinges”:

• The MBG heterocycle is limited to five families. Moving to a different heteroaryl class not in the list (for example, imidazoles if not captured, triazines not captured as MBG, etc.) can fall outside the literal scope unless the accused structure still satisfies an included MBG category.
• The skeleton uses difluoro-adjacent features suggested by the example compounds and by “1,1-difluoro” language embedded in the example names.
• R4 and R3 are broadly permissive, so enforcement relies more on getting the core scaffold right than on a single side-chain identity.
• R10 is restricted to specific groups: H, alkyl, Si(R12)3, phosphonate (P(O)(OH)2) and a specific O-CH2-P(O)(OH)2 motif, or C(O)alkyl optionally amino-substituted. Avoiding those groups likely reduces exposure against claims that read on phosphonate/silyl/amide-like variants.

What are the metalloenzyme-mediated and fungal mechanisms in the claim language?

Claims 1-2 frame the disease through “metalloenzyme-mediated.” Claims 3-5 frame the disease as fungal (or fungal growth) and microorganisms generally. The excerpt does not include the specification’s definition of which metalloenzyme class is targeted, so the analysis must focus on the claim wording itself.

Functional trigger risk

• For claims 1-2, the functional mechanism is “metalloenzyme-mediated disease” and “inhibiting metalloenzyme activity.”
• For claims 3-5, the trigger is “fungal disease” and “fungal growth” or “microorganism inhibition,” with no metalloenzyme requirement in those dependent claims.

This split is commercially significant: an accused product could still infringe the fungal-growth claims even if its biochemical MOA is challenged as not metalloenzyme-specific, unless the court reads “fungal” scope as independent of metalloenzyme language (as claim separation suggests).

Which fungal diseases and microorganism taxa are explicitly listed (claims 19-21)?

The extract provides enumerations that will matter for label-based infringement and method-of-use scope.

Claim 19: fungal diseases enumerated

The fungal disease/disorder is selected from:

• apple scab
• speckled leaf blotch of wheat
• leaf spot of sugarbeets
• leaf spot of peanut
• cucumber anthracnose
• wheat leaf rust
• grape powdery mildew
• wheat powdery mildew
• black sigatoka

Claim 20: fungal genera enumerated

The microorganism belongs to at least one genera selected from: Blumeria, Podosphaera, Sphaerotheca, Uncinula, Erysiphe, Puccinia, Phakopsora, Gymnosporangium, Hemileia, Uromyces, Alternaria, Cercospora, Cladosporium, Cochliobolus, Colletotrichum, Magnaporthe, Mycosphaerella, Phaeosphaeria, Pyrenophora, Ramularia, Rhyncosporium, Septoria, Venturia, Ustilago, Aspergillus, Penicillium, Drechslera, Fusarium, Botrytis, Gibberella, Rhizoctonia, Pseudocercosporella, Sclerotinia, Helminthosporium, Stagonospora, Exserohilum, Pyricularia.

Claim 21: fungal species enumerated

The microorganism is selected from:

• Venturia inaequalis
• Septoria tritici
• Cercospora beticola
• Cercospora arachidicola
• Colletotrichum lagenarium
• Puccinia graminis f. sp. tritici
• Puccinia recondita tritici
• Uncinula necator
• Blumeria graminis
• Mycosphaerella fijiensis

Enforcement consequence

These listings create a narrower set of method-of-use outcomes if the asserted claims are selected as dependents 19-21. But independent claims 3-5 (in the excerpt) already cover “fungal disease” and “fungal growth,” so the genus/species list is best read as additional fallback scope rather than the only infringement hook.

Which compounds are explicitly covered by claim 18, and how does that affect freedom-to-operate?

Claim 18 is effectively a claim-to-compound conversion. Each enumerated compound is a structure that “the compound is one of:” which generally eliminates ambiguity about whether that embodiment falls within Formula I.

What claim 18 implies

• If an accused product is a salt, ester, or formulation of one of the listed compounds, infringement is easier to prove for claims that require “a compound of Formula I.”
• If an accused product is a close analog not on the list, infringement depends on satisfying Formula I Markush limitations rather than on matching a specific example.

Scope note from the example naming

The listed compounds repeatedly contain the patterns:

• 1,1-difluoro propan-2-ol motif
• 2,4-difluorophenyl presence in many examples
• pyridine-2-yl or related heteroaryl substitutions
• MBG as tetrazolyl, pyrazolyl, triazolyl, oxazolyl, thiazolyl, etc., consistent with the MBG variable definition

This concentration indicates the likely “center of gravity” of the invention.

How strong is US 8,809,378’s patent estate based on the claim mechanics provided?

Strength analysis, based only on the claim text provided:

Strength factors

1. High Markush breadth on substituents: R3, R4, R5, R6, R7, R8, and R10 ranges are broad. This increases the chance that an accused scaffold is captured even if it tweaks peripheral groups.
2. Multiple therapeutic framing claims: metalloenzyme-mediated disease plus fungal-specific disease and growth plus microorganism inhibition creates multiple asserted pathways.
3. Explicit disease and genus/species lists: claim dependents 19-21 provide fallback coverage aligned with common plant pathology catalog targets.
4. Large explicit example set: claim 18’s compound list reduces argument space around what “Formula I” includes.

Weakness factors

1. Mechanism language can be litigated: “metalloenzyme-mediated” and “inhibiting metalloenzyme activity” are functional statements that may be challenged if the accused product’s MOA differs.
2. Dependents narrow aggressively: claims 6-17 focus on fluoro and specific phenyl substitution. If accused products avoid those, the dependents may not be used.
3. No formulation claim shown: the provided excerpt claims methods via contacting plant/seeds but does not show specific composition/formulation claims. If a product is marketed purely as a carrier-treated seed or delivered through a mechanism not meeting “contacting” as construed, scope could narrow.

What patent litigation, Orange Book status, or generics risks exist for US 8,809,378?

No information about litigation, FDA filings, registration status, or an Orange Book listing is provided, and this patent is not an FDA drug-substitution patent in the standard small-molecule/biologic sense. The provided excerpt also contains no application context that would link to an FDA pathway.

As a result, an accurate Paragraph IV-type analysis, Orange Book “status,” or biosimilar-style risk cannot be produced from the data provided.

What generic entry risks exist for agrochemical method claims like claims 1-5?

For agrochemical patents, the relevant “entry risk” is not a regulatory generic submission but whether competitors can legally market and use the same active structure or close analogs without practicing the claimed method.

Risk to generic/competitor actives

• Competitors copying Formula I actives run direct risk because claims require only contacting plants/seeds with the compound.
• Competitors pursuing different chemistries likely seek to exit the Markush envelope by changing MBG class, the core difluoro propan-2-ol substitution, or constrained functional groups like R10’s phosphonate/silyl patterns.

Risk to label strategy

Even if an accused product uses a covered compound, avoiding claimed disease presentations in labeling can be a defense depending on the jurisdiction and how “use” is pleaded and proven. Claims 19-21 make label-to-claim mapping more explicit when those dependents are asserted.

How should you compare this patent to neighboring patents within the same family?

A comparison requires the continuation/certification chain, publication numbers, and the specification’s defined Formula I structure. None of that file wrapper or family context is included in the prompt.

Because a “comprehensive and critical analysis of the claims and patent landscape” depends on the existence, timing, and scope of related family members, continuations, and continuations-in-part, no accurate landscape comparison is possible from the excerpt alone.

Key Takeaways

• US 8,809,378 is built around a broad “Formula I” Markush scaffold and multiple plant-contact method claims covering metalloenzyme-mediated disease outcomes and fungal growth/disease.
• Claims 19-21 provide specific fallback enumerations of fungal diseases, genera, and species that align with common plant pathology targets.
• Claim 18 lists over 100 specific compounds, creating a concrete infringement pathway when an accused active matches a listed embodiment.
• Enforcement strength likely concentrates on products that use Formula I compounds directly and that practice label- or evidence-aligned fungal disease indications. Mechanism and core-structure design-arounds are the most likely ways to reduce exposure.

FAQs

1) Does US 8,809,378 cover seed treatment specifically?
Yes, the method claims include “contacting a compound of Formula I with the plant or seeds,” which reads on seed treatments where the compound contacts the seeds.

2) Are metalloenzyme-related claims narrower than fungal claims?
Yes in claim language: claims 1-2 require “metalloenzyme-mediated” disease or “inhibiting metalloenzyme activity.” Claims 3-5 focus on fungal disease/growth or microorganisms without that metalloenzyme restriction.

3) What structural changes are most likely to avoid literal infringement?
Changes that move the active compound outside the MBG heterocycle set, outside the difluorinated propanol scaffold implied by the example set, or outside constrained R10 options (H/alkyl/silyl/phosphonate or specific carbonyl and amino-substituted variants).

4) Can a competitor infringe even if it avoids the listed fungal species?
Yes, because independent fungal method claims (3-5) are not limited to the specific species list; species/disease/genera enumerations appear in dependents 19-21.

5) How important is claim 18’s “compound is one of” list?
High for infringement mapping: a direct match to any listed compound provides a straightforward route to show the “compound of Formula I” limitation is satisfied.

References

1. US Patent 8,809,378 claim text provided in the prompt.

Details for Patent 8,809,378

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Aimmune Therapeutics, Inc.	PALFORZIA	peanut (arachis hypogaea) allergen powder-dnfp	Powder	125696	January 31, 2020		2032-06-19